Provenance of hires

A company tells you what it intends to do in its own time, in a language it controls — the press release, the concall, the annual report. But the people it hires to do that thing arrive first, and they arrive in public. Before a pharma company announces a push into complex US injectables, it hires the scientists who make them. Before a bank builds a wealth franchise, it hires the relationship head who has one. The intent is legible in the provenance of the hires — where the new senior people come from — months before it is legible in a filing.

This module is about reading that signal: a cluster of hires from a top-tier competitor as a serious move into their turf; a single specialist hire as a tell of what is coming next; the calibre of who agrees to join as a vote on the company's prospects by the best-informed people there are — and the reverse, a stream of senior exits or a just-hired star walking out, as an equally strong negative. It is Part Eight foresight in its most human form: reading the future from who is moving, before the financials move.

Reported numbers are the last record of a strategy, not the first. A new capability shows up in revenue years after the decision to build it — but it shows up in the org chart almost immediately, because you cannot build a capability without hiring the people who carry it. The hire is upstream of the capex, which is upstream of the revenue, which is upstream of the profit the market finally reprices on. Read the hire and you are reading the earliest link in that chain.

This is a specialised form of the scuttlebutt discipline built in Part Six (083): assembling public, individually-immaterial facts — a LinkedIn move here, a KMP change in a filing there, an appointment in the trade press — into a material conclusion the company has not yet stated. And it hands directly forward: reading provenance is one of the sharpest ways to see a developer, a lender or a manufacturer preparing to enter a business before its statements — which is why it enables the sector reads that follow (104).

There are four distinct signals in who joins and who leaves, and they are read from three public sources: professional-network moves (LinkedIn), the board and key managerial personnel (KMP) changes disclosed in filings and stock-exchange announcements, and appointment coverage in the trade press.

• A cluster from one top-tier rival. Several senior people leaving the same best-in-class competitor for the same company, into the same function, is the strongest positive: it is deliberate, funded capability-building, not chance. The source firm matters — poaching from the acknowledged leader in a capability is a statement about which capability is being built.
• A specific specialist. A single, telling hire — a regulatory-affairs head, a data-science leader, a named-geography sales head, a treasury or securitisation specialist — reveals what the company is about to do before it announces it. The role is the roadmap: you do not hire a US-FDA compliance head unless you are going to the US.
• The calibre of who agrees to join. A person who could go anywhere choosing this company is an informed insider's vote on its prospects; a marquee name joining a mid-cap is worth more scrutiny of the thesis, not less.
• The reverse — exits. A stream of senior people leaving to rivals, or the exit of a just-hired star before the work could pay off, is an equally strong negative: the same informed insiders withdrawing their vote. A departing independent director or a serial-exit pattern at the top is succession-and-confidence risk showing early.

The discipline that separates the signal from the churn is concentration and direction. Scattered hires across many functions are turnover; a concentrated cluster into one capability is intent. And the from and to matter as much as the who — a hire from the sector leader points differently from a lateral out of an unrelated industry.

A composite mid-cap formulations company, Kaveri Pharma illustrative, has announced nothing new about its strategy this year. [illustrative] Its statements look like more of the same domestic-generics business. But open its public hiring record. Over two quarters it has taken a regulatory-affairs head and two senior formulation scientists from the acknowledged #1 innovator in injectables, and a US-generics quality head from another top-tier peer — four senior people, from best-in-class sources, all into one capability: complex US injectables. No filing says "we are entering US injectables." The org chart already does.

Read against everything Part Eight builds, this is a runway forming before the financials show it: the capability is being assembled now, the capex and the ANDA filings will follow, and the revenue is years out. An investor reading only Kaveri's statements sees a static domestic-generics company; one reading the provenance of its hires sees a deliberate, funded move into a high-value export market, cast as a vote of confidence by four people who left the market leader to make it — visible quarters before the first press release. Now the negative: had those same four instead left Kaveri for a rival within a year of joining, the identical mechanism would read in reverse — an informed retreat from a capability the company could not, after all, build.

Provenance is not equally informative everywhere. It matters most where a single hire moves the needle — where one person carries a capability, a book of relationships, or a scarce skill that the business is built on. It matters least in a low-differentiation, process-driven business, where output comes from the plant and the process, not from any individual, and a marquee appointment changes little except the press release.

Reading who joins tells you intent and conviction; it does not tell you execution. A brilliant cluster of hires can still fail to build the capability — the strategy can be right and the delivery poor, the market can move, the resources can fall short. Provenance is a leading signal of what is being attempted, not a guarantee of what will be achieved.

It cannot give you timing or scale. The lead time between the hire and the visible result varies from quarters to years, and the hire tells you a push is coming without telling you how big or how soon it will land in the numbers. Being early on a real intent still means being early.

And a single move is not a verdict. One senior hire, or one exit, is a question, not an answer — people change jobs for money, geography, family and a hundred reasons unrelated to strategy or confidence. The confident read is never one move; it is a cluster — several hires into one capability, or several exits to rivals, pointing the same way, confirmed across LinkedIn, the KMP filings and the press. One departure is life; a pattern of departures is information.

The first trap is waiting for the announcement. The whole value of the signal is that it leads the press release; an investor who only acts on the formal strategy update is acting on information already in the price, having ignored the org chart that carried it for months.

The second is mistaking a marquee name for a strategy. A famous CXO joining a process-driven commodity business is often a vanity appointment that changes the letterhead and not the economics — the naive "big name equals big signal" is exactly the read the across-sectors section inverts. The signal lives in concentration, source and role, not celebrity.

The third is reading churn as intent, or intent as churn — treating scattered replacement hires as a grand plan, or dismissing a concentrated single-source cluster as routine turnover. The tell is always concentration and direction: where the people come from, and whether they converge on one capability or simply refill vacant chairs.

The fourth, and the one with a hard edge, is crossing the line from mosaic to inside information. Assembling public appointments into a conclusion is legitimate research; being told by a recruiter or an insider about a specific senior hire the company has not yet disclosed is material non-public information, and it does not become clean because it concerns people rather than numbers.